Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Julphar
Fish and Richardson
Medtronic
Accenture
Moodys
Mallinckrodt
Fuji
Cipla

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SUNITINIB MALATE

« Back to Dashboard

Clinical Trials for Sunitinib Malate

Trial ID Title Status Sponsor Phase Summary
NCT00137436 Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer Completed Pfizer Phase 1/Phase 2 This is a multi-center, open-label, Phase 1/2 study of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel and prednisone for the first-line treatment of metastatic hormone-refractory prostate cancer (mHRPC).
NCT00246571 Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer Completed Pfizer Phase 2 The purpose of this study is to compare progression free survival for SU011248 [sutent (sunitinib malate)] versus standard of care therapy in patients with previously treated, advanced, triple receptor negative (ER, PR, HER2) locally recurrent or metastatic breast cancer.
NCT00265798 Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate Active, not recruiting National Cancer Institute (NCI) Phase 2 This phase II trial is studying how well sorafenib works in treating patients with malignant gastrointestinal stromal tumor that progressed during or after previous treatment with imatinib mesylate and sunitinib malate. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Sunitinib Malate

Condition Name

Condition Name for Sunitinib Malate
Intervention Trials
Kidney Cancer 21
Stage IV Renal Cell Cancer 12
Stage III Renal Cell Cancer 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Sunitinib Malate
Intervention Trials
Carcinoma, Renal Cell 49
Carcinoma 35
Kidney Neoplasms 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Sunitinib Malate

Trials by Country

Trials by Country for Sunitinib Malate
Location Trials
United States 628
Canada 50
Japan 34
Korea, Republic of 20
China 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Sunitinib Malate
Location Trials
Texas 37
California 32
New York 31
Ohio 30
Illinois 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Sunitinib Malate

Clinical Trial Phase

Clinical Trial Phase for Sunitinib Malate
Clinical Trial Phase Trials
Phase 4 4
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Sunitinib Malate
Clinical Trial Phase Trials
Completed 78
Active, not recruiting 26
Terminated 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Sunitinib Malate

Sponsor Name

Sponsor Name for Sunitinib Malate
Sponsor Trials
National Cancer Institute (NCI) 66
Pfizer 53
M.D. Anderson Cancer Center 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Sunitinib Malate
Sponsor Trials
Other 96
Industry 72
NIH 69
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
AstraZeneca
Argus Health
Federal Trade Commission
Mallinckrodt
UBS
Merck
Cantor Fitzgerald
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.